【Product for Licensing】The Phase I ready Small Molecule with FIC potential in IBD

Project ID：BP-20240618-OR-061

Product Brief Summary

• Product Name: The Phase I ready Small Molecule with FIC potential in IBD
• Modality: Small Molecule
• Target: Tight junction proteins
• Therapeutic Area: Immunology-CD IBD
• Current Stage: China Phase 1 ready
• Rights Available: China/Global Right
• Collaboration Mode: License out

Current treatment status: Clinical needs not met

• The existing clinical medication is very limited, and the core treatment indicator “mucosal healing” is less than 50%;
• Patients need long-term medication, which is prone to relapse once stopped, and long-term use of existing drugs poses safety risks.

Treatment direction

• Mucosal healing
• High specificity of the site of intestinal inflammation
• A tool for dynamically tracking mucosal healing

MoA

• The product protected function of epithelial cell barrier in Caco-2 cell monolayer
• The product promoted expression of tight junction proteins in Caco-2 cell
• The product inhibited polarization of Th1/Th17 cells in naive T cell

Pharmaceutical effects on UC

(Acute model)

• The product ameliorated acute colitis induced by DSS in mice, including DAI and colorectum length.
• The product protected function of epithelial barrier in DSS-induced mice colitis model, including integrity and permeability.

(Chronic model)

• The product ameliorated chronic colitis induced by DSS in mice, including histological score and ulcer length.
• The product ameliorated chronic colitis induced by DSS in mice.
• The product decreased proinflammatory cytokines, like IL-1β, IL-6, IFN-γ and IL-17A in colon.

Pharmaceutical effects on CD

(Acute model)

• The product ameliorated acute colitis induced by TNBS in rats, including colorectum length and colorectal weight/length ratio.
• The product ameliorated acute colitis induced by TNBS in rats, including colorectum length and colorectal weight/length ratio.

Pharmaceutical effects on IBD

• The product ameliorated T cell transfer model of colitis in mice, including colorectal weight/length ratio and histological score.

DMPK

• Non-clinical PK studies have shown that the Product has a bioavailability of less than 1.0% and low exposure in the system.
• The product is mainly distributed in the digestive system of the stomach, small intestine, and large intestine.
• High Intestinal Exposure, Low System Exposure and Long-term medication safety

Contact

• If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!